1. Prevnar 13™ Pneumococcal 13-valent conjugate vaccine
Manufacturer: Wyerth
FDA Approval Date: 12/2011

2. Prevnar 13™ - Pneumococcal 13-valent conjugate Clinical Application
Indications:
Immunization of infants and children against Strep pneumoniae caused by included serotypes
Immunization of infants and children against otitis media caused by Strep pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F
Immunization of adults ≥50 years against pneumococcal pneumonia and invasive disease caused by included Strep pneumoniae serotypes

3. Prevnar 13™ - Pneumococcal 13-valent conjugate Clinical Application
Place in therapy:
Vaccination used to immunize patients as young as 6 weeks against various strains of Strep pneumoniae

4. Prevnar 13™ - Pneumococcal 13-valent conjugate Clinical Application
Contraindications:
Hypersensitivity
Warnings:
Apnea and Acute Illness
Precautions:
Use in pts w/ altered immunocompetence
Use in Elderly (>65yoa)

5. Prevnar 13™ - Pneumococcal 13-valent conjugate Clinical Application
Pregnancy: B
Lactation:
Excretion in breast milk unknown/use caution

6. Prevnar 13™ - Pneumococcal 13-valent conjugate Drug Facts
Pharmacology
Administered as a series of 4 injections given at 2, 4, 6, and months of age
Full efficacy w/in 1 month of the final vaccination

7. Prevnar 13™ - Pneumococcal 13-valent conjugate Drug Interactions
Drug Interactions – Precipitant Drugs
Belimumab: May the therapeutic effect of this Vaccine (inactivate)
Fingolimod: May the therapeutic effect of this Vaccine (inactivate)

8. Prevnar 13™ - Pneumococcal 13-valent conjugate Adverse Effects
Common Adverse Effects: (>10%)
Central nervous system: Chills, drowsiness, fatigue, fever, headache, insomnia, irritability
Dermatologic: Rash
Gastrointestinal: Appetite decreased
Local: Erythema, limitation of arm motion, pain, swelling, tenderness
Neuromuscular & skeletal: Arthralgia, myalgia

9. Prevnar 13™ - Pneumococcal 13-valent conjugate Monitoring Parameters
Efficacy Monitoring
None
Toxicity Monitoring

10. Cost: Estimated $430 for complete series
Prevnar 13™ - Pneumococcal 13-valent conjugate Prescription Information
Dosing:
Infants and Children 6 weeks-59 months: 0.5 mL/dose X 4 doses:
The first dose may be given as young as 6 weeks - 2 months.
The 3 remaining doses are usually given at 4, 6, and months
The recommended dosing interval is 4-8 weeks
The minimum interval between doses in children <1 year of age is 1 month
The minimum interval between the third and fourth dose is 2 months
Cost: Estimated $430 for complete series

11. Prevnar 13™ - Pneumococcal 13-valent conjugate vaccine Summary
Prevnar 13™ is the successor to the previously-marketed Prevnar® and is used in patients as young as 6 weeks.
Prevnar 13™ contains an additional 6 serotypes of Streptococcus pneumoniae, compared to the 7 serotypes provided in the original Prevnar® formulation.
The CDC has announced that young children appear to be at increased risk of febrile seizures when given the pneumococcal conjugate vaccine (PCV 13) at the same time as the inactivated influenza virus vaccine (TIV). The risk appears to be greatest from ages months. Because febrile seizures are typically benign and occur in 2% to 5% of all young children, the ACIP does not recommend a delay in administration of either vaccine or altering the vaccine schedule in any manner due to the potential risk of infection.

12. Prevnar 13™ - Pneumococcal 13-valent conjugate References
Prenvar-13 package insert. Wyerth Pharmaceuticals. Jan
Pubmed. MMWR Recomm Rep Dec 10;59(RR-11):1-18. Accessed 01/12.